Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 7/20 | 0.59 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TGM1 | P22735 | 1/20 | 0.45 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.45 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103284 | 0.86 | TGM2 (0.76) | TGM2EGFRLPAR1LPAR2BTK | |
| SCHEMBL22600367 | 0.81 | TGM2 (0.65) | TGM2EGFRLPAR1LPAR2BTK | |
| SCHEMBL6355891 | 0.81 | TGM2 (0.65) | TGM2EGFRLPAR1LPAR2 | |
| SCHEMBL13154807 | 0.81 | TGM2 (0.59) | TGM2EGFRLMNASRC | |
| SCHEMBL30684820 | 0.81 | TGM2 (0.59) | TGM2EGFRLMNASRC | |
| SCHEMBL15987129 | 0.80 | TGM2 (0.55) | TGM2EGFRBTKITKMAP2K7 | |
| SCHEMBL10294089 | 0.80 | RAB9A (0.64) | — | |
| SCHEMBL31536255 | 0.78 | TGM2 (0.65) | TGM2EGFRITKMAP2K7 | |
| SCHEMBL1383747 | 0.78 | TGM2 (0.65) | TGM2EGFRITKMAP2K7 | |
| SCHEMBL22600260 | 0.78 | BTK (0.52) | TGM2ACKR3EGFRBTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339596-A1 | FUROXAN-BASED COMPOUNDS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339596-A1 | FUROXAN-BASED COMPOUNDS AND USES THEREOF | PARK7, HTT, PRDX5 | TGM2 2258/4885ACKR3 3109/4885EGFR 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.